Schering Plough's Saphris Gets Strong Nod From FDA Panel
This article was originally published in The Pink Sheet Daily
Executive Summary
A safety profile showing less impact on weight and metabolic parameters than other atypical antipsychotics could set asenapine apart in crowded class if it is approved.